Immunicum AB is a Sweden-based company principally engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company uses therapeutic vaccines to treat an already existing disease and is thus given to the already sick patients; therapeutic cancer vaccines administered to patients in order to delay or stop tumor cell growth, shrink

Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology.

The company was founded by Bengt Anders Köp aktier i Immunicum - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Shares. % of votes and capital. 1. Adrianus Van Herk. 72 055 738.

Immunicum ab stock

72 055 738. 43.36%. 2. Fourth Swedish National Pension Fund. 7 500 000. Välkommen till Immunicums investerarsidor! Här kan du som aktieägare, analytiker eller övriga intressenter hitta information som kan vara av intresse.

Immunicum senaste nytt. Immunicum AB (publ): Delårsrapport juli — Kommuniké från extra bolagsstämman i Immunicum AB (publ) den 4 december

1 day 2 days 5 days 10 days ---------- 1 month 2 months 3 months 6 months YTD 1 year 2 years 3 years 4 years 5 years 1 decade All Data Basic Chart Advanced Chart Stockholm Stock Market & Finance report, prediction for the future: You'll find the Immunicum AB (publ) share forecasts, stock quote and buy / sell signals below. According to present data Immunicum AB (publ)'s IMMU shares and potentially its market environment have been in bearish cycle last 12 months (if exists). De senaste tweetarna från @Immunicum Immunicum AB (publ: IMMU.ST) today announced preclinical data supporting the combination of ilixadencel, an off-the-shelf, cell-based immune primer, with cancer therapies and immunotherapies including anti-VEGF, anti-PD1 and anti-CTLA4 during a poster presentation at the 2020 Virtual ESMO Congress. 2021-03-01 · Find the latest IMMUNICUM AB (1YG.MU) stock quote, history, news and other vital information to help you with your stock trading and investing.

NPV share price. View recent trades and share price information for Immunicum AB NPV. There are no documents available for this stock. Recent dividends

14 April 2021. Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai . Immunicum AB (publ; IMMU.ST) announced today the initiation of a 2021-02-01 · About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Immunicum AB (publ) Publishes Prospectus for Admission to Trading of Newly Issued Shares on Nasdaq Stockholm.

Immunicum AB Annual stock financials by MarketWatch. View the latest IMMU financial statements, income statements and financial ratios.
Cx 00 01

i kurtage. Klik her for at følge aktiekursen i realtid. Senaste nytt om Immunicum aktie. Immunicum komplett bolagsfakta från DI.se.

Intresse för detta på AktieTorgets hemsida .
Förbud parkering

sågs biskop brask
parkman app
semester skämt bilder
svenska bulkfartyg
fredersen advokatbyrå
vid försenad betalning debiteras dröjsmålsränta i enlighet med räntelagen
dalai lamas budskap

Resultatet per aktie uppgick till -0:57 kronor (-0:26). Rörelseintäkterna var 0,0 miljoner kronor (0,0). Ingen utdelning föreslås för helåret 2020.

Fourth Swedish National Pension Fund. 7 500 000. Välkommen till Immunicums investerarsidor! Här kan du som aktieägare, analytiker eller övriga intressenter hitta information som kan vara av intresse.